Premium
RESVEGA in exudative age‐related macular degeneration
Author(s) -
Kubicz A.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0704
Subject(s) - medicine , macular degeneration , ophthalmology , visual acuity , fluorescein angiography , retinal
Purpose The aim of this clinical case is to present the improvement of retinal structure and stabilisation of visual acuity using RESVEGA (trans‐resveratrol and omega‐3 fatty acids i.a.) in a patient with exudative AMD. Methods A 84‐year‐old female patient with pseudophakia and history of dry AMD in both eyes and atrophic changes in the left eye presented in mid‐January 2015 with deterioration of vision in the right eye. VOD: 0.1, no improvement with correction; VOS: counts fingers from 1.5 m. In the OCT: subretinal fluid, suspected CNV in the right eye, atrophic changes in the left eye. Recommended: fluorescein angiography, qualification for intravitreal anti‐VEGF injection into RE and supplementation with RESVEGA (2 tablets daily at once). FFA – increasing hyperfluorescence in the RE macula, leakage from CNV and changes of atrophic character in the course of AMD. February 2015 (qualification for intravitreal anti‐VEGF injection): RE: significant improvement in OCT, decreased fluid space under the sensory retina. VOD, VOS as previously. Injections were abandoned; recommended: continued supplementation with RESVEGA, frequent ophthalmic examinations. Mid‐March 2015: in the OCT no fluid spaces. VOD, VOS as previously. Recommended: observation and continued supplementation as so far. September 2015: in the OCT – no fluid spaces. VOD, VOS as previously. Results Owing to the use of RESVEGA, regression of the subretinal fluid was obtained. It was possible not to introduce the intravitreal anti‐VEGF injection. The oral therapy ensured maintaining stable ophthalmological status and visual acuity on the same level within 9 months of observation. Conclusions RESVEGA supplementation allowed to maintain stable condition of patient's eyes, without anti‐VEGF injection.